|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/02/20 DelMar Pharmaceuticals, Inc. S-4/A 7/01/20 76:11M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: S-4/A Pre-Effective Amendment to Registration of HTML 3.41M
Securities Issued in a Business-Combination
Transaction
2: EX-5.1 Opinion of Counsel re: Legality HTML 31K
3: EX-8.1 Opinion of Counsel re: Tax Matters HTML 29K
4: EX-10.43 Material Contract HTML 102K
5: EX-23.3 Consent of Experts or Counsel HTML 23K
6: EX-23.4 Consent of Experts or Counsel HTML 22K
7: EX-99.1 Miscellaneous Exhibit HTML 29K
8: EX-99.2 Miscellaneous Exhibit HTML 26K
9: EX-99.3 Miscellaneous Exhibit HTML 23K
10: EX-99.4 Miscellaneous Exhibit HTML 23K
17: R1 Cover HTML 38K
18: R2 Condensed Consolidated Interim Balance Sheets HTML 86K
19: R3 Condensed Consolidated Interim Balance Sheets HTML 45K
(Parenthetical)
20: R4 Condensed Consolidated Interim Statements of HTML 68K
Operations
21: R5 Condensed Consolidated Interim Statements of HTML 143K
Stockholders' Equity
22: R6 Condensed Consolidated Interim Statements of Cash HTML 88K
Flows
23: R7 Nature of Operations, Corporate History, and Going HTML 44K
Concern
24: R8 Significant accounting policies HTML 91K
25: R9 Valent Technologies LLC agreements HTML 29K
26: R10 Derivative liabilities HTML 64K
27: R11 Stockholders' equity HTML 218K
28: R12 Related party transactions HTML 29K
29: R13 Current and deferred income taxes HTML 46K
30: R14 Commitments and contingencies HTML 29K
31: R15 Supplementary statement of cash flows information HTML 35K
32: R16 Financial risk management HTML 39K
33: R17 Subsequent events HTML 46K
34: R18 Financial instruments HTML 34K
35: R19 Significant accounting policies (Policies) HTML 142K
36: R20 Significant accounting policies (Tables) HTML 30K
37: R21 Derivative liabilities (Tables) HTML 60K
38: R22 Stockholders' equity (Tables) HTML 185K
39: R23 Current and deferred income taxes (Tables) HTML 44K
40: R24 Supplementary statement of cash flows information HTML 34K
(Tables)
41: R25 Financial risk management (Tables) HTML 33K
42: R26 Nature of Operations, Corporate History, and Going HTML 42K
Concern (Detail)
43: R27 Significant Accounting Policies (Detail) HTML 69K
44: R28 Significant accounting policies - Schedule of HTML 30K
derivative liabilities under the fair value
hierarchy (Detail)
45: R29 Valent Technologies LLC Agreements - Additional HTML 44K
Information (Detail)
46: R30 Derivative Liabilities - Additional Information HTML 56K
(Detail)
47: R31 Derivative Liabilities - Schedule of derivative HTML 43K
liabilities (Detail)
48: R32 Derivative Liabilities - Schedule of derivative HTML 47K
liabilities 1 (Detail)
49: R33 Stockholders' Equity (Deficiency) (Textual) HTML 133K
(Detail)
50: R34 Stockholders' Equity (Deficiency) (Textual 2) HTML 86K
(Detail)
51: R35 Stockholders' Equity (Deficiency) (Textual 3) HTML 131K
(Detail)
52: R36 Stockholders' equity (deficiency) - Schedule of HTML 55K
outstanding under the legacy plan (Detail)
53: R37 Stockholders' Equity (Deficiency) - Schedule of HTML 49K
valuation assumptions using a Black-Scholes
pricing model (Detail)
54: R38 Stockholders' equity (deficiency) - Summary of HTML 106K
stock options currently outstanding and
exercisable (Detail)
55: R39 Stockholders' Equity (Deficiency) - (Textual 4) HTML 84K
(Detail)
56: R40 Stockholders' equity (deficiency) - Schedule of HTML 34K
stock-based compensation expense (Detail)
57: R41 Stockholders' equity (deficiency) - Summary of HTML 51K
unvested stock options (Detail)
58: R42 Stockholders' Equity (Deficiency) - Schedule of HTML 75K
warrants (Detail)
59: R43 Stockholders' Equity (Deficiency) - Schedule of HTML 46K
warrants (Parenthetical) (Detail)
60: R44 Stockholders' Equity (Deficiency - Summary of HTML 39K
changes in outstanding warrants (Detail)
61: R45 Stockholders' Equity (Deficiency) - Summary of HTML 86K
outstanding warrants (Detail)
62: R46 Related Party Transactions - Additional HTML 32K
Information (Detail)
63: R47 Current and Deferred Income Taxes - Components of HTML 50K
future tax assets and deferred tax liabilities
(Detail)
64: R48 Current and Deferred Income Taxes - Additional HTML 52K
Information (Detail)
65: R49 Current and Deferred Income Taxes - Schedule of HTML 47K
difference between income tax rate and statutory
income tax rate (Detail)
66: R50 Commitments and Contingencies - Additional HTML 33K
Information (Detail)
67: R51 Supplementary Statement of Cash Flows Information HTML 40K
- Schedule of supplementary statement of cash
flows information (Detail)
68: R52 Financial Risk Management - Additional Information HTML 50K
(Detail)
69: R53 Financial Risk Management - Schedule of balances HTML 32K
in foreign currencies (Detail)
70: R54 Financial Risk Management - Schedule of fair value HTML 32K
of off-balance sheet risks (Detail)
71: R55 Subsequent Events - Additional Information HTML 112K
(Detail)
72: R56 Stockholders' Equity - Schedule of Conversion of HTML 36K
Series B Preferred stock to common stock (Detail)
73: R57 Financial Instruments - Additional Information HTML 26K
(Detail)
75: XML IDEA XML File -- Filing Summary XML 132K
74: EXCEL IDEA Workbook of Financial Reports XLSX 113K
11: EX-101.INS XBRL Instance -- dmpi-20200331 XML 2.13M
13: EX-101.CAL XBRL Calculations -- dmpi-20200331_cal XML 145K
14: EX-101.DEF XBRL Definitions -- dmpi-20200331_def XML 762K
15: EX-101.LAB XBRL Labels -- dmpi-20200331_lab XML 1.39M
16: EX-101.PRE XBRL Presentations -- dmpi-20200331_pre XML 1.05M
12: EX-101.SCH XBRL Schema -- dmpi-20200331 XSD 236K
76: ZIP XBRL Zipped Folder -- 0001193125-20-185478-xbrl Zip 205K
| EX-23.4 |
Exhibit 23.4
CONSENT OF INDEPENDENT AUDITORS
We consent to the use in this Registration Statement on Form S-4 of DelMar Pharmaceuticals, Inc. of our report dated April 9, 2020 relating to the consolidated financial statements of Adgero Biopharmaceuticals Holdings, Inc. and Subsidiary, which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Rosenberg Rich Baker Berman & Company
Somerset, New Jersey
| This ‘S-4/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 7/2/20 | 3, 424B3, EFFECT | ||
| Filed on: | 7/1/20 | |||
| 4/9/20 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/13/24 Kintara Therapeutics, Inc. S-4 28:10M Donnelley … Solutions/FA 10/27/23 Kintara Therapeutics, Inc. S-1/A 12:1.2M Donnelley … Solutions/FA 10/24/23 Kintara Therapeutics, Inc. S-1/A 20:2.4M Donnelley … Solutions/FA 10/04/23 Kintara Therapeutics, Inc. S-1 13:1.1M Donnelley … Solutions/FA 9/18/23 Kintara Therapeutics, Inc. 10-K 6/30/23 75:12M Donnelley … Solutions/FA 9/27/22 Kintara Therapeutics, Inc. 10-K 6/30/22 79:15M Donnelley … Solutions/FA 9/28/21 Kintara Therapeutics, Inc. 10-K 6/30/21 79:13M ActiveDisclosure/FA 10/26/20 Kintara Therapeutics, Inc. S-3 4:1.5M ActiveDisclosure/FA 9/18/20 Kintara Therapeutics, Inc. 10-K 6/30/20 71:9.9M ActiveDisclosure/FA 9/01/20 Kintara Therapeutics, Inc. 8-K:1,3,5,7 8/31/20 4:300K EdgarAgents LLC/FA 8/25/20 Kintara Therapeutics, Inc. 8-K:1,3,5,7 8/20/20 4:190K EdgarAgents LLC/FA 8/21/20 Kintara Therapeutics, Inc. 8-K:1,2,3,5 8/17/20 8:1.4M EdgarAgents LLC/FA |